Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label immunogenicity and safety study of CH5-AS (HPAIV_H5N8) in healthy adults
jRCT2031240648Phase 2Active, not recruiting
- Sponsor
- Strategic Center of Biomedical Advanced Vaccine Research and Development for Preparedness and Response : SCARDA, Japan Agency for Medical Research and Development
- Start
- Jan 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CH5-AS in Influenza A infection, sponsored by Strategic Center of Biomedical Advanced Vaccine Research and Development for Preparedness and Response : SCARDA, Japan Agency for Medical Research and Development. Primary endpoint: Immunogenicity against A/H5 subtype avian influenza virus. Started Jan 2025; status: active, not recruiting.
02
Drugs
CH5-AS
03
Conditions
Influenza A infection
Beyond the preview
Go deeper on jRCT2031240648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240648.